← Back to headlines
Novartis Shares Drop After Late-Stage Heart Drug Trial Fails
Novartis stock declined sharply after a late-stage clinical trial for a new cholesterol-lowering medication failed to meet its primary efficacy targets. The setback raises questions about the pharmaceutical giant's near-term pipeline but is considered manageable by industry analysts.
7 Sept, 08:12 — 7 Sept, 08:18
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (54/100)5 sources33/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center3
Center (3)
investing-commorningstarReuters
Right2
Right (2)
nzzwsj
Far R
Geographic diversity— 3 regions13/34
US3Switzerland1Intl1
Sources
Showing 3 of 5 sources
ReutersVery High8h ago
Novartis falls as failed cholesterol drug study raises stakes for pipeline - Reuters
Novartis falls as failed cholesterol drug study raises stakes for pipeline Reuters
Read full article →wsjHigh8h ago
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial - WSJ
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial WSJ
Read full article →morningstar8h ago
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial - Morningstar
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial Morningstar
Read full article →Coverage Timeline
First report: Reuters · 7 Sept, 08:12|Full coverage: 5 · 7h|Window: 7h
Left-leaningCenterRight-leaning
